Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Napo nets £3.15mm with private financing

Executive Summary

Napo Pharmaceuticals, a US firm that lists on the London Stock Exchange, netted £3.15mm ($6.17mm) in a private placement of 3.5mm shares at £0.95 each (market average) to undisclosed investors. The company will use the funds to move its NP500 into Phase II trials for Type II diabetes and metabolic syndrome, and to explore a low-dose version of its Phase III crofelemer for HIV/AIDS-related diarrhea.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies